Literature DB >> 26067744

Association between colchicine resistance and vitamin D in familial Mediterranean fever.

Ismail Ozer1, Turkan Mete2, Ozlem Turkeli Sezer3, Guyem Kolbasi Ozgen4, Gultekin Ozan Kucuk5, Coskun Kaya6, Elif Kilic Kan2, Gulhan Duman2, Hacer Pinar Ozturk Kurt7.   

Abstract

Although colchicines are the only effective treatment of familial Mediterranean fever (FMF), resistance to colchicines (CR) which is observed in up to 30% of the patients is still a problem. Clinically, resistance to colchicine is defined as three or more attacks within the last 6 months period while using ≥2 mg/day colchicine. Previous studies have shown decreased vitamin D levels in FMF patients compared with healthy controls. The aim of this study is to evaluate whether vitamin D levels differ between CR and non-CR FMF patients. This study included 64 FMF patients who were being followed in Nephrology Clinic of Samsun Research and Education Hospital for at least 1 year. FMF was diagnosed according to the criteria defined by Livneh et al. Serum 25-hydroxy vitamin D (25-OHD) concentration (ng/mL) was detected in all FMF patients who were not in an acute attack period. From 64 patients 29 were accepted as CR. Mean 25-OHD level was 9.39 ± 1.00 ng/mL in CR patients and 18.48 ± 1.09 ng/mL in colchicine responsive patients (p < 0.001). Plasma vitamin D levels were significantly lower in colchicine resistant patients. Vitamin D deficiency may be a factor in etiopathogenesis of CR. Studies in larger patient samples that particularly evaluate the response to vitamin D replacement in CR FMF patients are needed.

Entities:  

Keywords:  Colchicines; familial Mediterranean fever; resistance to colchicines; vitamin D

Mesh:

Substances:

Year:  2015        PMID: 26067744     DOI: 10.3109/0886022X.2015.1056064

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

1.  Microtubules as a potential platform for energy transfer in biological systems: a target for implementing individualized, dynamic variability patterns to improve organ function.

Authors:  Yaron Ilan
Journal:  Mol Cell Biochem       Date:  2022-07-13       Impact factor: 3.842

2.  Seasonal residual activity in adult familial Mediterranean fever: a longitudinal observational study.

Authors:  Sevtap Acer Kasman; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-06-08       Impact factor: 3.580

3.  Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.

Authors:  Binita Shah; Michael Pillinger; Hua Zhong; Bruce Cronstein; Yuhe Xia; Jeffrey D Lorin; Nathaniel R Smilowitz; Frederick Feit; Nicole Ratnapala; Norma M Keller; Stuart D Katz
Journal:  Circ Cardiovasc Interv       Date:  2020-04-16       Impact factor: 6.546

Review 4.  Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy.

Authors:  Esther Forkosh; Ariel Kenig; Yaron Ilan
Journal:  Pharmacol Res Perspect       Date:  2020-08

5.  Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

Authors:  Ahmet Omma; Berkan Armaǧan; Serdar Can Güven; Sevinç Can Sandıkçı; Seda Çolak; Çiǧdem Yücel; Orhan Küçükşahin; Abdulsamet Erden
Journal:  Front Pediatr       Date:  2021-11-29       Impact factor: 3.418

Review 6.  The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

Authors:  Eitan Giat; Ilan Ben-Zvi; Merav Lidar; Avi Livneh
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

7.  [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Sahr; U Kiltz; C Weseloh; T Kallinich; J Braun
Journal:  Z Rheumatol       Date:  2020-09-30       Impact factor: 1.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.